ZyVersa Therapeutics (ZVSA)
OTHER OTC:ZVSA
Want to see ZVSA full AI Analyst Report?
Top Page
ZyVersa Therapeutics
(OTC:ZVSA)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.17
▲(27.69% Upside)
Action:Downgraded
Date:05/14/26
The score is primarily constrained by very weak financial performance (no revenue, large losses, heavy cash burn, and deeply negative equity with rising debt). Technical indicators also lean bearish (negative MACD, weak RSI, and price below key short- and mid-term moving averages). Valuation offers little offset because the company is loss-making (negative P/E) and provides no dividend yield.
Positive Factors
Focused clinical-stage pipeline in renal and inflammatory diseases
ZyVersa runs a focused clinical-stage strategy with two distinct candidates (VAR 200 and IC 100) addressing renal and inflammasome-driven inflammatory indications. A concentrated, indication-driven pipeline can sustain strategic clarity, partnership interest, and targeted clinical progress over the next several months.
Negative Factors
Material balance sheet deterioration and large equity deficit
Deeply negative equity and rapidly rising debt relative to assets indicate severe capital structure stress, limiting financial flexibility. This elevates refinancing, covenant, and counterparty risk and weakens the company's ability to fund trials without dilutive or onerous financing terms over coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused clinical-stage pipeline in renal and inflammatory diseases
ZyVersa runs a focused clinical-stage strategy with two distinct candidates (VAR 200 and IC 100) addressing renal and inflammasome-driven inflammatory indications. A concentrated, indication-driven pipeline can sustain strategic clarity, partnership interest, and targeted clinical progress over the next several months.
Read all positive factors
ZyVersa Therapeutics (ZVSA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.42M
Dividend YieldN/A
Average Volume (3M)51.59K
Price to Earnings (P/E)―
Beta (1Y)1.37
Revenue GrowthN/A
EPS Growth57.26%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.32
Shares Outstanding8,095,921
10 Day Avg. Volume65,792
30 Day Avg. Volume51,592
Financial Highlights & Ratios
PEG Ratio0.63
Price to Book (P/B)-0.06
Price to Sales (P/S)0.00
P/FCF Ratio-156.26
Enterprise Value/Market Cap634.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-36.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-65.8
Revenue Forecast (FY)N/A
ZyVersa Therapeutics Business Overview & Revenue Model
Company Description
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat foc...
How the Company Makes Money
null...
ZyVersa Therapeutics Financial Statement Overview
Summary
Income Statement
7
Very Negative
Balance Sheet
5
Very Negative
Cash Flow
6
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -6.93K | -10.40K | -10.40K | -10.40K |
| EBITDA | -24.34M | -25.29M | -9.14B | -107.74M | -14.43M | -7.25M |
| Net Income | -1.82B | -24.95M | -9.41B | -98.30M | -14.05M | -8.08M |
Balance Sheet | ||||||
| Total Assets | 742.22M | 347.90M | 20.60M | 22.11M | 118.51M | 1.13M |
| Cash, Cash Equivalents and Short-Term Investments | 302.66M | 101.78M | 1.53M | 3.14M | 5.90M | 328.58K |
| Total Debt | 1.20B | 0.00 | 0.00 | 8.66K | 108.76K | 9.15M |
| Total Liabilities | 14.87B | 12.73B | 12.08M | 11.04M | 18.51M | 13.63M |
| Stockholders Equity | -14.12B | -12.39B | 8.52M | 11.07M | 99.99M | -12.50M |
Cash Flow | ||||||
| Free Cash Flow | -2.62B | -5.11M | -7.56M | -8.72M | -1.49M | -5.08M |
| Operating Cash Flow | -2.62B | -5.11M | -7.56M | -8.72M | -4.89M | -5.08M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 2.83B | 3.69M | 5.95M | 5.96M | 1.87M | 5.23M |
ZyVersa Therapeutics Technical Analysis
Neutral
0.13
Price Trends
0.20
Negative
0.21
Negative
0.18
Positive
Market Momentum
>-0.01
Positive
45.38
Neutral
7.75
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZVSA, the sentiment is Neutral. The current price of 0.13 is below the 20-day moving average (MA) of 0.19, below the 50-day MA of 0.20, and below the 200-day MA of 0.18, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.38 is Neutral, neither overbought nor oversold. The STOCH value of 7.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ZVSA.
ZyVersa Therapeutics Risk Analysis
ZyVersa Therapeutics disclosed 86 risk factors in its most recent earnings report. ZyVersa Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ZyVersa Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
ZVSA
ZyVersa Therapeutics
0.20
-0.45
-69.42%
SCNI
Scinai Immunotherapeutics
0.41
-2.14
-83.84%
ADTX
Aditxt
0.06
-37,588.25
-100.00%
CERO
CERo Therapeutics Holdings
0.01
-9.08
-99.87%
PBM
Psyence Biomedical
3.51
-30.99
-89.83%
CDT
CDT Equity
0.74
-537.26
-99.86%
ZyVersa Therapeutics Corporate Events
Private Placements and Financing
ZyVersa Therapeutics Announces $1 Million Convertible Note Financing
Neutral
Mar 5, 2026
On February 27, 2026, ZyVersa Therapeutics entered into a Securities Purchase Agreement with accredited investors for a $1 million private placement of convertible promissory notes and accompanying Series A-4 common stock purchase warrants. The no...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.